Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Challenges in optimizing preexposure prophylaxis development, engagement, and access for HIV prevention
Eileen P. Scully, … , Ethel D. Weld, Joel N. Blankson
Eileen P. Scully, … , Ethel D. Weld, Joel N. Blankson
Published November 11, 2019
Citation Information: J Clin Invest. 2019;129(12):5071-5073. https://doi.org/10.1172/JCI134389.
View: Text | PDF
Viewpoint

Challenges in optimizing preexposure prophylaxis development, engagement, and access for HIV prevention

  • Text
  • PDF
Abstract

Authors

Eileen P. Scully, Ethel D. Weld, Joel N. Blankson

×

Figure 1

HIV infection risk and PrEP prescriptions in the United States.

Options: View larger image (or click on image) Download as PowerPoint
HIV infection risk and PrEP prescriptions in the United States.
(A) Esti...
(A) Estimated proportions of people living in the United States at risk for HIV infection (2015 data) and distribution of PrEP prescriptions in 2016 among the subset for whom race/ethnicity data is available. (B) Risk versus prescription frequency among men and women (2015 data). Figure based on data in refs. 19, 21.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts